^
Association details:
| Biomarker: | TMB-H + PD-L1 overexpression |
|---|---|
| Cancer: | Fibrosarcoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient
Published date:
03/26/2021
Excerpt:
A 42-year-old male...showed a high-grade myxofibrosarcoma...About 40% to 50% of tumor cells in his pulmonary tissues were showed positive PD-L1 expression and his tumor mutational burden was 215Muts....The administration of the target drug Anlotinib was carried out. However, the tumor showed no response to Anlotinib...myxofibrosarcoma with no response to conventional therapeutic options, immunotherapy is a promising selection.
DOI:
10.1097/MD.0000000000025262
